Cargando…

Antibody response and safety of inactivated SARS-CoV-2 vaccines in chronic hepatitis B patients with and without cirrhosis

BACKGROUND: The immune response and safety of inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines among patients with chronic hepatitis B (CHB), especially those with cirrhosis, are not clear. Therefore, this study was conducted to evaluate the efficacy and safety of in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Huanhuan, Huang, Yufei, Zhong, Chunxiu, Liao, Xingmei, Tan, Wenjuan, Zhao, Siru, Guo, Liangxu, Fan, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230951/ https://www.ncbi.nlm.nih.gov/pubmed/37266421 http://dx.doi.org/10.3389/fimmu.2023.1167533

Ejemplares similares

Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B
por: Liao, Xingmei, et al.
Publicado: (2023)

The gut–liver axis in immune remodeling of hepatic cirrhosis
por: Guan, Huayu, et al.
Publicado: (2022)

Editorial: Hepatic immune response underlying liver cirrhosis and portal hypertension
por: Guo, Yangkun, et al.
Publicado: (2023)

Risk Factors Associated With Quality of Life in Patients With Hepatitis B Virus Related Cirrhosis
por: Zhang, Qi, et al.
Publicado: (2022)

Dysregulation of innate cell types in the hepatic immune microenvironment of alcoholic liver cirrhosis
por: Ren, Ao, et al.
Publicado: (2023)

Analysis of neutralizing antibodies to COVID-19 inactivated or subunit recombinant vaccines in hospitalized patients with liver dysfunction
por: Li, Hu, et al.
Publicado: (2023)

Evaluating SARS-CoV-2 antibody reactivity to natural exposure and inactivated vaccination with peptide microarrays
por: Zheng, Peiyan, et al.
Publicado: (2023)

Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study
por: Wen, Gui-Ping, et al.
Publicado: (2023)

Etiology of end-stage liver cirrhosis impacts hepatic natural killer cell heterogenicity
por: Maretti-Mira, Ana C., et al.
Publicado: (2023)

Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years
por: Zhu, Hong-Hong, et al.
Publicado: (2023)

The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity
por: Keshtkar-Jahromi, Maryam, et al.
Publicado: (2020)

Neutralizing Antibody Response in Dogs and Cats Inoculated with Commercial Inactivated Rabies Vaccines
por: SHIRAISHI, Rikiya, et al.
Publicado: (2013)

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults
por: Wu, Yufei, et al.
Publicado: (2023)

Pre-Existing Cross-Reactive Antibody Responses Do Not Significantly Impact Inactivated COVID-19 Vaccine-Induced Neutralization
por: Wang, Jin, et al.
Publicado: (2021)

Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination
por: Wang, Fuzhen, et al.
Publicado: (2022)

Efficacy and Safety of Sofosbuvir and Velpatasvir Combination for the Treatment of Chronic Hepatitis C in Patients With or Without Cirrhosis
por: Shah, Islam, et al.
Publicado: (2021)

Electron-Beam Inactivation of Human Rotavirus (HRV) for the Production of Neutralizing Egg Yolk Antibodies
por: Skrobarczyk, Jill W., et al.
Publicado: (2022)

Editorial: Community series in hepatic immune response underlying liver cirrhosis and portal hypertension, volume II
por: Lan, Tian, et al.
Publicado: (2023)

Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer
por: Song, Rui, et al.
Publicado: (2022)

Hepatitis C Vaccines, Antibodies, and T Cells
por: Shoukry, Naglaa H.
Publicado: (2018)

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
por: Chen, Yaping, et al.
Publicado: (2022)

The shaping of gut immunity in cirrhosis
por: Muñoz, Leticia, et al.
Publicado: (2023)

Long-term efficacy and safety of different corticosteroid courses plus mycophenolate mofetil for autoimmune encephalitis with neuronal surface antibodies without tumor
por: Li, Dong, et al.
Publicado: (2023)

Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine
por: Melo-González, Felipe, et al.
Publicado: (2021)

Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old
por: Medeiros, Giuliana X., et al.
Publicado: (2022)

Pilot genome-wide association study of antibody response to inactivated SARS-CoV-2 vaccines
por: Li, Ping, et al.
Publicado: (2022)

Heat Shock Protein 70 Serum Levels Differ Significantly in Patients with Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma
por: Gehrmann, Mathias, et al.
Publicado: (2014)

Immunity and Fibrogenesis: The Role of Th17/IL-17 Axis in HBV and HCV-induced Chronic Hepatitis and Progression to Cirrhosis
por: Paquissi, Feliciano Chanana
Publicado: (2017)

Seroprevalence of hepatitis A antibodies in patients with cirrhosis of liver
por: Jain, Mayank
Publicado: (2022)

Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer
por: Han, Yuling, et al.
Publicado: (2022)

Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study
por: Li, Hong-Yan, et al.
Publicado: (2022)

Safety monitoring in inactivated COVID-19 vaccines by clinical pharmacists from a single center in China
por: Hu, Min, et al.
Publicado: (2022)

Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies
por: Wang, Lan, et al.
Publicado: (2022)

Safety and Efficacy of Hepatitis B Vaccination in Cirrhosis of Liver
por: Roni, D. Ajith, et al.
Publicado: (2013)

Hepatic hydrothorax without ascites as the first sign of liver cirrhosis
por: Kim, Jung Soo, et al.
Publicado: (2015)

Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells
por: Yi, Qiuyun, et al.
Publicado: (2023)

Cirrhosis Hampers Early and Rapid Normalization of Natural Killer Cell Phenotype and Function in Hepatitis C Patients Undergoing Interferon-Free Therapy
por: Perpiñán, Elena, et al.
Publicado: (2020)

Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days
por: Xu, Qiu-Yan, et al.
Publicado: (2021)

The duration and breadth of antibody responses to 3-dose of inactivated COVID-19 vaccinations in healthy blood donors: An observational study
por: Ou, Shanhai, et al.
Publicado: (2022)

Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
por: Xin, Yujing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r1ohds8stmand61ua05ub5reev